JD HEALTH Reports Strong Q3 Growth, Forecasts Full-Year Revenue of RMB70.8–71.5 Billion, Up 21.8%–22.9% YoY

Deep News12-10

1. **Full-Year Performance Outlook for JD HEALTH** As of December 10, 2025, consensus estimates based on Choyang Yongxu’s quarterly performance forecast project the company’s full-year revenue at RMB70.8–71.5 billion, reflecting year-on-year growth of 21.8%–22.9%. Net profit is expected to reach RMB4.4–5.3 billion, up 6.1%–26.4%, while adjusted net profit is anticipated to grow 18.2%–32.3% to RMB5.7–6.3 billion. Investors should monitor whether actual results exceed expectations upon the earnings release. Choyang Yongxu’s Hong Kong stock quarterly performance forecasts will provide further insights.

2. **Latest Analyst Views on JD HEALTH** **Haitong International Securities** noted that JD HEALTH delivered robust growth in both revenue and profit for Q3 2025. Revenue rose 28.7% YoY to RMB17.1 billion, with net profit surging 97.2% to RMB1.8 billion. The company raised its full-year guidance, projecting ~22% revenue growth and adjusted profit of ~RMB6.2 billion. Key drivers included strong performance in pharmaceuticals and advertising, efficient marketing spend, and expansion in instant retail, which is expected to attract more upstream partnerships and scale benefits.

- **Pharmaceuticals & Advertising**: Sustained high growth, with accelerated momentum in health supplements. - **Marketing Efficiency**: Offline pharmacy investments were lower than expected. - **Instant Retail**: Leveraging infrastructure to attract upstream collaborations and enhance economies of scale.

**MinSheng Securities** highlighted JD HEALTH’s Q3 revenue of RMB17.1 billion (+28.7% YoY), with operating profit and Non-IFRS profit up 125.3% and 42.4%, respectively. The company made strides in expanding医保 coverage (serving ~200 million users online), upgrading its service network, growing merchant partnerships (over 150,000), and scaling AI healthcare services (surpassing 50 million users for its AI Jingyi platform). Strategic collaborations with top pharmaceutical firms strengthened its high-end supply chain, while a partnership with Wuhan Union Hospital advanced digital healthcare services, including smart outpatient platforms.

**Risk Warning**: The data or cases presented are for reference only and should not be the sole basis for investment decisions. Market volatility, corporate performance, and policy changes may impact stock prices. Investors should conduct thorough research and assess risk tolerance before investing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment